BioLineRx Receives Notice of Allowance for US Patent on BL-7010
News Aug 22, 2014
BioLineRx Ltd. has announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming the use of BL-7010, a novel polymer in preventing or decreasing gluten’s deleterious effects on the gastrointestinal mucosa.
This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and uses thereof are granted or pending in the US, Europe, Japan, Canada, Israel, India, China, Brazil, Russia, Australia, South Africa and Hong Kong.
“We are very pleased to receive this Notice of Allowance for the BL-7010 patent in the prevention of gluten toxicity, which significantly broadens our coverage in the United States,” stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx.
Dr. Savitsky continued, “We recently announced unblinded results of a Phase 1/2 safety study for BL-7010, in which the compound was shown to have no systemic exposure. This is of significance since it may support classification of BL-7010 as a medical device in Europe, accelerating its pathway to commercialization. We are currently in the final stages of the Phase 1/2 safety study in order to select the optimal dose of BL-7010 for the upcoming efficacy study, which we look forward to commencing early next year.”
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE